0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

ARTIFICIALLY INDUCED FEVER FOR THE TREATMENT OF GONOCOCCIC INFECTIONS IN THE MALE

STAFFORD L. WARREN, M.D.; WINFIELD W. SCOTT, M.D.; CHARLES M. CARPENTER, M.D.
JAMA. 1937;109(18):1430-1435. doi:10.1001/jama.1937.02780440020006.
Text Size: A A A
Published online

With the advance of chemotherapy, numerous drugs have been developed and used for the treatment of gonorrhea with the hope that a preparation might be found which was capable of quickly destroying the gonococcus without injuring the mucous membrane of the male urethra. The inadequacy of chemical treatment, in all probability, has been due to the anatomic structure of the male urethra and to the tendency of the gonococcus to become "fast" to germicides used locally. Search for a specific drug for intravenous use has likewise been disappointing. Comparatively recently, however, two related products, prontosil1 and prontylin (sulfanilamide), have been heralded by a few investigators as specifics for meningococcic and gonococcic infections. While we have been using sulfanilamide in our clinic for some time, we feel that further studies must be made before its clinical value can be definitely determined. Antigonococcus serums, vaccines, filtrates, bacteriophages and the like have

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();